Mucormycosis: A Co-infection Associated with - COVID-19 and Diabetes

Abstract

Background: Rhino-orbital mucormycosis cases in patients with coronavirus disease are on the rise, particularly in India. In severe Mucormycosis and COVID-19, Diabetes mellitus is a risk factor on its own. The use of steroids and different immunosuppressive drugs to handle significantly ill sufferers has broadly spread because the COVID-19 pandemic has advanced, which has probably contributed to a boom in subordinate infections and uncontrolled blood glucose levels. Initial symptoms include fever, headache, nausea, and widespread weakness. With the start of sinusitis, purulent discharge with or without epistaxis and congestion and reduced feeling within the nose may be present. Mucormycosis is an uncommon, difficult to identify condition with high morbidity and mortality rates. Patient survival depends on early detection, rapid treatment , and consideration of the limitations of continually updating COVID-19 therapeutic recommendations.
 Objective: ‘The purpose of the study was to conduct a systemic review of the literature’ for determining the severity and co-relation of diabetes with mucormycosis.
 Methodology: Keywords were used to search the articles from the electronic databases of PubMed, Cochrane and Google Scholar upto August, 2021. All details of case reports/articles of mucormycosis in COVID-19 were utilized for this review article.
 Study Design: Systemic Review article
 Conclusions: 1. Using a literature review of all documented cases, we can comment on the correlation of diabetes with Mucormycosis in covid-19 patients.
 
 Based on the observations gained from the literature examined in this study, we are able to decide the clinical diagnostic strategy for mucormycosis in diabetic patients affected by covid-19.
 
 Study Implication: This review article ensured the clinical diagnostic strategy and management in such cases affected by covid-19.